{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:32:21Z","timestamp":1745929941700,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40256-022-00561-6","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T02:02:41Z","timestamp":1672106561000},"page":"113-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials"],"prefix":"10.1007","volume":"23","author":[{"given":"Nathaniel","family":"Eraikhuemen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalonda Barnes","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dovena","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Hawkins","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaretta L.","family":"Kearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8569-8211","authenticated-orcid":false,"given":"Valerie","family":"Marcellus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13098-017-0225-1","volume":"9","author":"MC Bertoluci","year":"2017","unstructured":"Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25. https:\/\/doi.org\/10.1186\/s13098-017-0225-1.","journal-title":"Diabetol Metab Syndr"},{"key":"561_CR2","doi-asserted-by":"publisher","unstructured":"Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34(2):S101\u20136. https:\/\/doi.org\/10.2337\/dc11-s202.","DOI":"10.2337\/dc11-s202"},{"issue":"7","key":"561_CR3","doi-asserted-by":"publisher","first-page":"E294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140(7):E294\u2013324. https:\/\/doi.org\/10.1161\/CIR.0000000000000691.","journal-title":"Circulation"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. The present and future implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"561_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52\u201360. https:\/\/doi.org\/10.1001\/jama.2015.7008.","journal-title":"JAMA"},{"issue":"9131","key":"561_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"R Turner","year":"1998","unstructured":"Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(98)07037-8.","journal-title":"Lancet"},{"issue":"2","key":"561_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/nejmoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N EnglJ Med. 2009;360(2):129\u201339. https:\/\/doi.org\/10.1056\/nejmoa0808431.","journal-title":"N EnglJ Med"},{"issue":"5","key":"561_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O Marsenic","year":"2009","unstructured":"Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875\u201383. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.031.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"561_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/nejmoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/nejmoa2030183.","journal-title":"N Engl J Med"},{"key":"561_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106049","author":"Y Li","year":"2022","unstructured":"Li Y, Xu G. Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges. Pharmacol Res. 2022. https:\/\/doi.org\/10.1016\/j.phrs.2021.106049.","journal-title":"Pharmacol Res"},{"key":"561_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01272-z","author":"C Zheng","year":"2021","unstructured":"Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2021. https:\/\/doi.org\/10.1186\/s12933-021-01272-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"561_CR12","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"561_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772\u2013810. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.022.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"561_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657\u201365. https:\/\/doi.org\/10.1001\/jama.2015.3656.","journal-title":"JAMA"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Andrew Moore R, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"issue":"3","key":"561_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obesity Metabol. 2017;19(3):387\u201393. https:\/\/doi.org\/10.1111\/dom.12829.","journal-title":"Diabetes Obesity Metabol"},{"issue":"9","key":"561_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704. https:\/\/doi.org\/10.1016\/S2213-8587(18)30141-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"561_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/nejmoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/nejmoa1611925.","journal-title":"N Engl J Med"},{"key":"561_CR19","unstructured":"Melillo G. FDA removes Canagliflozin's boxed warning for amputations. AJMC. 2020. https:\/\/www.ajmc.com\/view\/fdaremoves-canagliflozin-s-boxed-warning-for-amputations. Accessed 16 Dec 2022."},{"issue":"4","key":"561_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/nejmoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/nejmoa1812389.","journal-title":"N Engl J Med"},{"issue":"22","key":"561_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"M Bernard Zinman","year":"2015","unstructured":"Bernard Zinman M, Christopher Wanner M, et al. Empagloflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"561_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/nejmoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335. https:\/\/doi.org\/10.1056\/nejmoa2004967.","journal-title":"N Engl J Med"},{"issue":"21","key":"561_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"15","key":"561_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/nejmoa2024816.","journal-title":"N Engl J Med"},{"issue":"15","key":"561_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/nejmoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"561_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/nejmoa2107038.","journal-title":"N Engl J Med"},{"issue":"24","key":"561_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/nejmoa1811744.","journal-title":"N Engl J Med"},{"key":"561_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.664533","author":"C Chen","year":"2021","unstructured":"Chen C, Peng H, Li M, et al. Patients with type 2 diabetes mellitus and heart failure benefit more from sodium-glucose cotransporter 2 inhibitor: a systematic review and meta-analysis. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.664533.","journal-title":"Front Endocrinol"},{"issue":"4","key":"561_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/dom.14286","volume":"23","author":"GA Silverii","year":"2021","unstructured":"Silverii GA, Monami M, Mannucci E. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials. Diabetes Obesity Metabol. 2021;23(4):1052\u20136. https:\/\/doi.org\/10.1111\/dom.14286.","journal-title":"Diabetes Obesity Metabol"},{"issue":"1","key":"561_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(1):19\u201336. https:\/\/doi.org\/10.1007\/s00592-016-0892-7.","journal-title":"Acta Diabetol"},{"issue":"11","key":"561_CR31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.amjcard.2016.08.061","volume":"118","author":"H Tang","year":"2016","unstructured":"Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118(11):1774\u201380. https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.061.","journal-title":"Am J Cardiol"},{"issue":"2","key":"561_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14. https:\/\/doi.org\/10.3390\/diseases8020014.","journal-title":"Diseases"},{"key":"561_CR33","doi-asserted-by":"crossref","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. 2013. Available from www.annals.org. Accessed 26 Nov 2022.","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"issue":"4","key":"561_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/nejmoa1515920.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00561-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:36:25Z","timestamp":1678462585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00561-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00561-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"16 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nathaniel Eraikhuemen, Simon Leung, Shalonda Barnes Warren, Dovena Lazaridis, Carla Hawkins Smith, Margaretta L. Kearson, and Valerie Marcellus have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"NE: research design, data acquisition and interpretation, drafting, critical revision of the manuscript, model development and analyses, and interpretation of results; SL: research design, drafting, critical revision of the manuscript, model development and analyses, and interpretation of results; SBW: research design, data acquisition and interpretation, drafting, and critical revision of the manuscript; DL: research design and critical revision of the manuscript; CHS: research design and critical revision of the manuscript; MLK: research design and critical revision of the manuscript; and VM: research design, data acquisition and interpretation, and critical revision of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}